Savara (SVRA)

NasdaqMarkedet er stengt

Savara Inc. er et bioteknologiselskap i klinisk fase som utvikler behandlinger for sjeldne luftveissykdommer, med særlig fokus på tilstander som har begrensede godkjente behandlingsalternativer. Selskapets arbeid er sentrert rundt spesiallegemidler for luftveissystemet, der sykdomsbiologi, administrasjonsmåte og pasientpopulasjon krever målrettede utviklingsstrategier fremfor brede kommersielle modeller for primærhelsetjenesten.

Savaras ledende program er molgramostim, en inhalert formulering av rekombinant humant granulocytt-makrofag-kolonistimulerende faktor, eller GM-CSF. Kandidaten studeres for autoimmun pulmonal alveolær proteinose, ofte forkortet aPAP, en sjelden lungesykdom der nedsatt fjerning av surfaktant fører til opphopning av materiale i alveolene og kan redusere oksygenoverføringen. Ved å levere GM-CSF direkte til lungene er molgramostim utviklet for å adressere den underliggende mangelen i immunsignaleringen som er knyttet til sykdommen.

Selskapets investeringscase er tett knyttet til den kliniske og regulatoriske fremdriften for molgramostim, som er i fase 3-utvikling. Som for mange bioteknologiselskaper innen sjeldne sykdommer avhenger Savaras verdi av vellykkede prøveresultater, samhandling med regulatoriske myndigheter, produksjonsberedskap, beskyttelse av immaterielle rettigheter og evnen til å betjene en liten, men medisinsk betydningsfull pasientgruppe. Det opererer ikke som en diversifisert farmasøytisk produsent; i stedet konsentrerer det ressursene om et smalt terapeutisk område der spesialistkunnskap og fokusert klinisk gjennomføring står sentralt.

Savara har hovedkontor i USA og handles på Nasdaq under tickeren SVRA. Investorer følger vanligvis selskapet for utviklingen innen sjelden lungemedisin, kliniske data i sen fase, regulatoriske milepæler og den potensielle kommersielle muligheten for en inhalasjonsbehandling ved aPAP.

5.37USD
+0.00(0.00%)

Sist oppdatert

Markedsverdi
$1,103,320,281
P/E-tall
P/FCF-tall
P/S-tall
Selskapsverdi
$1,091,629,281
Sektor
Materials
Bransje
Pharmaceutical Preparations
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX, 78746
globenewswire.com

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

24. jan. 2026, 17:38 P.M.
globenewswire.com

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

06. nov. 2025, 02:57 A.M.
globenewswire.com

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

03. nov. 2025, 00:47 A.M.
globenewswire.com

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

31. okt. 2025, 00:32 A.M.
globenewswire.com

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

30. okt. 2025, 18:46 P.M.
globenewswire.com

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Savara Inc.

29. okt. 2025, 02:39 A.M.
globenewswire.com

SVRA DEADLINE ALERT: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

28. okt. 2025, 03:10 A.M.
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

27. okt. 2025, 17:00 P.M.
globenewswire.com

SVRA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

26. okt. 2025, 14:31 P.M.
globenewswire.com

SVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – SVRA

25. okt. 2025, 01:55 A.M.
globenewswire.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRA

22. okt. 2025, 00:47 A.M.
globenewswire.com

SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th Deadline

18. okt. 2025, 17:39 P.M.
globenewswire.com

SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action Lawsuit

17. okt. 2025, 22:52 P.M.
globenewswire.com

Savara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA

16. okt. 2025, 22:00 P.M.
globenewswire.com

SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

16. okt. 2025, 18:00 P.M.
globenewswire.com

SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Important Deadline in Lawsuit

16. okt. 2025, 00:00 A.M.
globenewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SVRA

15. okt. 2025, 22:00 P.M.
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

14. okt. 2025, 19:57 P.M.
globenewswire.com

Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors – Contact The Gross Law Firm

13. okt. 2025, 22:00 P.M.
globenewswire.com

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

12. okt. 2025, 14:44 P.M.
Markedsverdi
$1,103,320,281
Selskapsverdi
$1,091,629,281
P/E-tall
P/B-tall
7.68
P/S-tall
EV / EBITDA-forhold
-7.6
EV / omsetning
Resultat per aksje
-0.68
Utbytterente
0%
P/FCF-tall
P/CF-tall
Fri kontantstrøm
-$110,660,000
Avkastning på egenkapital
-96.97%
Avkastning på eiendeler
-72.5%
Gjeld / egenkapital
0.21
Likviditetsgrad I
10.13
Likviditetsgrad II
10.13
Kontanter
2.38
Snittvolum
$1,552,685
Fundamentalpris (snapshot)
5.37

Regnskap er ikke tilgjengelig for denne noteringen.

TypeRapportDatoLenke
edgar index10-Q — Savara IncVis rapport
edgar indexS-8 — Savara IncVis rapport
edgar index4 — Savara IncVis rapport
form 4Form 4 — Lutz Robert MatthewVis rapport
form 4Form 4 — Lutz Robert MatthewVis rapport
edgar index4 — Savara IncVis rapport
edgar index144 — Savara IncVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
edgar index8-K — Savara IncVis rapport
eight k text8-K — 8-KVis rapport
edgar index10-Q — Savara IncVis rapport
edgar indexDEF 14A — Savara IncVis rapport
edgar indexDEFA14A — Savara IncVis rapport
edgar indexARS — Savara IncVis rapport
edgar indexPRE 14A — Savara IncVis rapport
edgar index4 — Savara IncVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
form 4Form 4 — Lowrance David LVis rapport
edgar index10-K — Savara IncVis rapport
edgar index8-K — Savara IncVis rapport
eight k text8-K — 8-KVis rapport
ten k section10-K — businessVis rapport
ten k section10-K — mdaVis rapport
ten k section10-K — risk_factorsVis rapport
edgar indexSCHEDULE 13G/A — Savara IncVis rapport
edgar index4 — Savara IncVis rapport
edgar indexSCHEDULE 13G/A — Savara IncVis rapport
form 4Form 4 — McCracken Joseph SVis rapport
form 4Form 4 — McCracken Joseph SVis rapport
edgar indexSCHEDULE 13G/A — Savara IncVis rapport
edgar indexSCHEDULE 13G/A — Savara IncVis rapport
edgar indexSCHEDULE 13G/A — Savara IncVis rapport
edgar index8-K — Savara IncVis rapport
eight k text8-K — 8-KVis rapport
edgar indexSCHEDULE 13G — Savara IncVis rapport
edgar index8-K — Savara IncVis rapport
eight k text8-K — 8-KVis rapport
edgar index4 — Savara IncVis rapport
form 4Form 4 — RAMSAY DAVID AVis rapport
edgar index144 — Savara IncVis rapport
edgar index4 — Savara IncVis rapport